Search Result

Results for "

wild-type p53

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apoptosis (8) Autophagy (3) Deubiquitinase (1) E1/E2/E3 Enzyme (6) Ferroptosis (1) HIF/HIF Prolyl-Hydroxylase (2) JNK (1) MDM-2/p53 (18) Microtubule/Tubulin (2) Mixed Lineage Kinase (1) Parasite (2) PROTACs (1)
By Research Areas:	Cancer (20) Infection (2) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18343A

CP-31398 dihydrochloride	MDM-2/p53	Cancer
CP-31398 dihydrochloride stabilizes the active conformation of *p53* and promotes p53 activity in cancer cell lines with mutant or wild-type p53 .

HY-12025

Serdemetan 2 Publications Verification JNJ-26854165	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

HY-18634

NSC319726 ZMC1	MDM-2/p53	Cancer
NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.

HY-122578

P53R3	MDM-2/p53	Cancer
P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 ^R175H, p53 ^R248W and p53 ^R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 ^M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .

HY-144105

NSC405640	MDM-2/p53	Cancer
NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

HY-16271

Kevetrin hydrochloride 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of *p53, induces apoptosis in TP53 wild-type* and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .

HY-120122

PK7088	Others	Cancer
PK7088 is a pyrazole and a specific peptide. PK7088 supports the reactivation of mutant p53 by converting it to a form exhibiting wild-type properties. PK7088 exhibit anticancer activity in cancer research .

HY-19896

COTI-2 2 Publications Verification	MDM-2/p53 Apoptosis	Cancer
COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .

HY-136910

USP7-IN-7	Deubiquitinase	Cancer
USP7-IN-7 (compound 124) is a USP7 inhibitor with an IC₅₀ value ＜10 nM. USP7-IN-7 shows cytotoxicity against p53-mutant cancer cell lines, p53 wild-type blood cancer and neuroblastoma cell lines with low nanomolar values. USP7-IN-7 can be used for cancer research .

HY-13811

NSC697923 1 Publications Verification	E1/E2/E3 Enzyme Apoptosis	Cancer
NSC697923 is a potent UBE2N (ubiquitin-conjugating enzyme E2 N, Ubc13) inhibitor. NSC697923 induces neuroblastoma (NB) cell death via promoting nuclear importation of p53 in p53 wild-type NB cells. NSC697923 also induces cell death in p53 mutant NB cells by activation of JNK-mediated apoptotic pathway. NSC697923 inhibits DNA damage and NF-κB signaling. Antitumor activity .

HY-10029

Nutlin-3a Maximum Cited Publications 34 Publications Verification Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas .

HY-B0413

Fenbendazole 5 Publications Verification	Parasite HIF/HIF Prolyl-Hydroxylase Microtubule/Tubulin Antibiotic	Infection
Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .

HY-B0413S

Fenbendazole-d3 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase Parasite Microtubule/Tubulin Antibiotic	Infection
Fenbendazole-d₃ is a deuterium labeled Fenbendazole. Fenbendazole-d₃ is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].

HY-110088

SCH529074 1 Publications Verification	MDM-2/p53	Cancer
SCH529074 is a potent and orally active *p53* activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a K_i of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .

HY-16664

SJ-172550 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
SJ-172550 is a small molecule inhibitor of MDMX; competes for the wild type p53 peptide binding to MDMX with an EC₅₀ of 5 μM.

HY-19980

Eprenetapopt 5+ Cited Publications APR-246; PRIMA-1Met	MDM-2/p53 Autophagy Apoptosis Ferroptosis	Cancer
Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .

HY-134823

MD-222	MDM-2/p53 PROTACs E1/E2/E3 Enzyme	Cancer
MD-222 is the first-in-class highly potent PROTAC degrader of MDM2. MD-222 consists of ligands for Cereblon and MDM2. MD-222 induces rapid degradation of the MDM2 protein and activation of wild-type p53 in cells. MD-222 has anticancer effects .

HY-122753

SLMP53-1	MDM-2/p53	Cancer
SLMP53-1 is a wild-type and mutant *p53* reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .

HY-153202

SLMP53-2	MDM-2/p53 Apoptosis	Cancer
SLMP53-2 is a mutant *p53* reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .

HY-10412

CEP-1347 KT7515	JNK Mixed Lineage Kinase MDM-2/p53	Neurological Disease
CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type *p53* .

HY-139458

MDM2-IN-21

MDM-2/p53 Cancer

MDM2-IN-21 is a potent MDM2 inhibitor. MDM2-IN-21 can be used for the research of cancer .
HY-150620

BI-0282

MDM-2/p53 Cancer

BI-0282 (Compound 1) is a potent MDM2-p53 interaction inhibitor .

MDM2-IN-21	MDM-2/p53	Cancer
MDM2-IN-21 is a potent MDM2 inhibitor. MDM2-IN-21 can be used for the research of cancer .

BI-0282	MDM-2/p53	Cancer
BI-0282 (Compound 1) is a potent MDM2-p53 interaction inhibitor .

Fenbendazole-d3 2 Publications Verification
Fenbendazole-d₃ is a deuterium labeled Fenbendazole. Fenbendazole-d₃ is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.